<DrugInformationSummary id="CDR0000815042"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Lifileucel is a type of tumor-infiltrating lymphocyte (TIL) therapy. TIL therapy involves removing immune cells from a patient’s tumor and testing them in the lab to find out which ones best recognize the tumor cells. The selected immune cells are then grown in large numbers in the lab and given back to the patient to help their immune system kill the tumor cells. </DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/lifileucel">Lifileucel</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000769186">lifileucel</TerminologyLink><GlossaryLink ref="CDR0000815033">lifileucel</GlossaryLink><USBrandNames><USBrandName>Amtagvi</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>LIH-fih-LOO-sel</TermPronunciation><MediaLink ref="CDR0000815697" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000815698" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b0c63a-9a7e-46d0-a562-dc0d7d7867f3&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Lifileucel</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=91b0c63a-9a7e-46d0-a562-dc0d7d7867f3&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Lifileucel
         is approved to treat:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045135" dictionary="Cancer.gov" audience="Patient">Melanoma</GlossaryTermRef>.</Strong> It is used in adults whose cancer has spread to other parts of the body or cannot be removed by surgery. It is used when the cancer did not respond or stopped responding to an antibody that blocks <GlossaryTermRef href="CDR0000777027" dictionary="Cancer.gov" audience="Patient">PD-1</GlossaryTermRef> and, if the cancer has an abnormal <GeneName><GlossaryTermRef href="CDR0000561325" dictionary="Cancer.gov" audience="Patient">BRAF</GlossaryTermRef></GeneName> gene, a <GlossaryTermRef href="CDR0000750801" dictionary="Cancer.gov" audience="Patient">BRAF inhibitor</GlossaryTermRef> with or without a <GlossaryTermRef href="CDR0000798762" dictionary="Cancer.gov" audience="Patient">MEK inhibitor</GlossaryTermRef>.</ListItem>
   </ItemizedList>
  <Para id="_4"> Lifileucel is approved under FDA’s <ExternalRef xref="https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm">Accelerated Approval Program</ExternalRef>. As a condition of approval, <GlossaryTermRef href="CDR0000799146" dictionary="Cancer.gov" audience="Patient">confirmatory trial(s)</GlossaryTermRef> must show that it provides a clinical benefit in these patients.</Para><Para id="_5">Lifileucel
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Lifileucel</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/769186">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers">Understanding the Risk of Second Cancers After CAR T-Cell Therapy</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/news-events/cancer-currents-blog/2024/fda-amtagvi-til-therapy-melanoma">First Cancer TIL Therapy Gets FDA Approval for Advanced Melanoma</ExternalRef></Para><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/t-cell-transfer-therapy">T-cell Transfer Therapy</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C120552">Find Clinical Trials for Lifileucel</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2024-03-26</DateFirstPublished><DateLastModified>2025-01-07</DateLastModified></DrugInformationSummary>
